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ABSTRACT
Known as the guardian of the genome, transformation-related protein 53 (TRP53) 
is a well -known tumor suppressor. Here, we describe a novel TRP53 deficient mouse 
model on a tumor prone background—SJL/J mice. The absence of TRP53 (TRP53 
nullizygosity) leads to a shift in the tumor spectrum from a non-Hodgkin’s-like 
disease to thymic lymphomas and testicular teratomas at a very rapid tumor onset 
averaging ~12 weeks of age. In haplotype studies, comparing tumor prone versus 
tumor resistant Trp53 null mouse strains, we found that other tumor suppressor, 
DNA repair and/or immune system genes modulate tumor incidence in TRP53 null 
strains, suggesting that even a strong tumor suppressor such as TRP53 is modulated 
by genetic background. Due to their rapid development of tumors, the SJL/J TRP53 
null mice generated here can be used as an efficient chemotherapy or immunotherapy 
screening mouse model.
INTRODUCTION
The product of the transformation-related protein 
(Trp53) is one of the most researched tumor suppressors 
in biomedical research, with currently more than 97,000 
research/review articles published to date. Known as the 
guardian of the genome, the function of TRP53 protein 
(TP53, or, in humans, p53) has been well studied, 
and its functions include transcriptional regulation, 
DNA repair, cell cycle check-point control, apoptosis, 
autophagy and senescence (for review, see [1-9]). The 
lack of a functional p53 gene product in humans leads 
to Li-Fraumeni syndrome predisposing the patient to a 
spectrum of early-onset cancers (for review, see [10-12]). 
Importantly, it has been shown that since p53 in humans 
is located at a distal end of chromosome 17 (17p13.1), 
the loss of this piece of chromosome, and thereby p53, 
generally accelerates cancers [3, 13].
Since TRP53 has many crucial functions in 
biological systems, a number of mouse models have been 
made in order to elucidate TRP53 function more fully 
[14-18]. Of principal note here, Trp53 mutations have 
been shown to synergize with loss-of-function mutations 
in other tumor suppressor genes generally accelerating 
tumor development and progression. For example, p53 
deficiency synergizes with: Rb deficiency in a conditional 
mouse model to produce metastatic prostate cancer 
[19]; NUP98 translocation in a NUP98-HOXD13–
driven mouse model to accelerate complications of 
myelodysplastic syndrome [20]; and mutations in Apc to 
promote mammary neoplasia [21]. Hence, the disrupting 
of TRP53 has become a tool to accelerate the growth 
of tumors that develop from mutations in other tumor 
suppressor genes allowing more rapid and efficient study 
of these tumors. 
Swiss Jim Lambert (SJL/J) mice, developed from 
three different sources of Swiss Webster mice, have 
become widely used owing to their high incidence of 
reticulum cell sarcomas. They develop lymphomas within 
their first year [22-31] that resemble Hodgkin’s disease 
[23-25] as well as B-cell non-Hodgkin’s lymphomas 
[26-31]. In the presence of IL-21, the tumors arising 
from SJL/J mice resemble human angioimmunoblastic 
T-cell lymphoma [22]. In addition to cancer models, 
these mice have been used as models for experimental 
autoimmune encephalomyelitis (EAE) [32], aggression 
[33], spontaneous myopathy in limb girdle muscular 
dystrophy [34], and cardiovascular disease, due to their 
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resistance to developing atherosclerotic aortic lesions 
even on high fat diet [35]. The SJL/J strain is highly 
susceptible to mouse adenovirus 1, making it also a 
model for infectious disease studies [36]. Therefore, the 
SJL/J strain of mice is a highly valued disease model 
to test therapeutics for a diversity of conditions and 
diseases.
We previously used these mice to test to what 
extent the chemotherapeutic 2-deoxy-D-glucose (2DG) 
can alleviate the tumor burden of SJL/J mice exhibiting 
terminal stages of cancer [37]. 2DG is a structural 
analog to glucose and blocks glycolysis leading to 
intracellular ATP depletion, sensitizing tumor cells to 
radiation therapy and chemotherapy [38]. However, 
2DG at high doses show hypoglycemic and adverse 
cardiac effects, and at tolerable doses fail to show a 
significant antitumor effect in many in vivo experiments 
in both mice and humans [39]. Our 2DG studies in 
SJL/J mice were primarily conducted to test to what 
extent this toxic chemotherapeutic could have reduced 
adverse effects when combined with other compounds. 
At doses that did not elicit adverse effects, 2DG alone 
given to mice with a SJL/J background was able to 
significantly shrink tumors [37]. However, the tumors 
develop resistance to 2DG after four weeks, after 
which the tumor growth re-emerges [37]. Although the 
penetrance of spontaneous tumorigenesis in SJL/J is 
>95%, the time it takes to develop such tumors is ~one 
year, with a range between nine months to 1.2 years [24]. 
This protracted pathogenesis means that it is difficult 
to generate sufficient cohorts of mice to be tested in a 
timely fashion. Therefore, to address this challenge, 
we hypothesized that removing Trp53 would accelerate 
tumor development, and thereby enable the ability to test 
the efficacy of novel combinations of chemotherapies or 
immunotherapies within a more operationally convenient 
timespan.
Here, we generate a TRP53 null SJL/J mice using 
CRISPR Cas9 with two guide RNAs aimed at deleting 
exon 4 of the Trp53 gene. Upon analysis, TRP53 was 
expressed in +/+ mice, reduced in heterozygous mice, 
and absent in -/- mice. Homozygous null mice showed 
a significantly shorter time of onset of tumorigenesis, 
and a reduced survival, with tumors being detected as 
early as 11 weeks of age, faster than all the other models 
commonly available. However, we also found that the 
ablation of TRP53 in SJL/J mice shifted the tumor 
spectrum to thymic lymphomas, testicular teratomas and 
rhabdomyosarcomas rather than the typical Hodgkin’s/
non-Hodgkin’s lymphomas that SJL/J wild type mice 
develop. This unexpected shift in tumor spectrum to 
thymic lymphomas is observed with TRP53 mutations in 
other strains such as C57BL6/J, 129S1, BALB/c, FVB/
NJ, and C3H/J, suggesting that deregulation of TRP53 
leads to specific types of cancers depending upon the 
genetic background [14-18]. We further interrogated 
the haplotypes of these strains, comparing tumor-prone 
TRP53 null strains versus the non-tumor-prone strains, 
and found that a majority of the alleles that modulate 
the tumor incidence rate have either cancer, immune 
system or DNA-repair related functions. The immune 
system and DNA repair systems are known to be critical 
in regulating tumorgenesis. This result suggests that not 
even a strong tumor suppressor gene such as Trp53 is 
canalized, and the genetic background will modify the 
resulting neoplasticity. 
RESULTS
Generation of Trp53-/- SJL/J mice
Based on the ENSEMBL database (Release 98), 
exon 3 of TRP53 is the first exon that is sufficiently 
large enough to generate guides that can target the gene. 
Furthermore, functional domains of TRP53 are further 
downstream of this exon, thus targeting this exon to 
introduce a frame shift mutation is anticipated to lead to 
a null mutation. According to the ENSEMBL database, 
Trp53 transcripts contain 5’UTR sequences that include 
ATG sequences that could be putative translational 
start sites. Thus, herein exon 3 is designated as exon 4, 
assuming that upstream starts sites yield an additional 
exon. 
To generate p53 knockout alleles in the SJL/J 
mouse strain, superovulated female mice were mated 
and zygotes were collected for microinjection. Of the 28 
resulting offspring, 15 (54%) had modifications at one 
or both target sites; six had deletions of the intervening 
sequence between each guide and thus considered 
“dropouts.” Founder dropout candidates were crossed 
with wild type SJL/J mice and N1 heterozygotes 
were genotyped to characterize the mutant alleles. 
One allele was ultimately selected to establish a new 
mutant mouse strain (Figure 1A, 1B), designated SJL/J-
Trp53<em2Mvw>/Mvw JAX stock 33940 (i.e. a 176bp 
deletion; ∆176). Genotyping and characterization of 
mutant alleles was accomplished using PCR (FWD: 
5’- TCCAGACTTCCTCCAGAAGATA, REV:5’-
CCTCTGTGCTTGGCTTCA) and Sanger sequencing. 
The wild type PCR product is 624bp and the ∆176 
mutant allele results in a 448bp amplicon (Figure 1C).
The mutant allele was maintained in heterozygous 
mice. Heterozygous mice were mated to obtain the null, 
heterozygous or wild type alleles. Breeding outcomes 
showed that the allele frequency was below expected 
Mendelian ratios for the homozygotes at 1:3:1=wild 
type:heterozygous:null alleles (data from 10 litters, with 
litter sizes of ~ 5 mice). However, all mice (i.e., null, 
heterozygous, wild type) survive through weaning at a 
frequency similar to that of the parental SJL/J strain. 
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Detection of TRP53 protein
From the nucleotide sequences, it is predicted 
that the ∆176 allele should yield a stop codon after 69 
residues (predicted 7.8kDa), leaving the transactivation 
domain intact but deleting all domains downstream 
(Figure 1D). Intact TRP53 is predicted to be 42.5kD, 
however, the protein appears around 53kDa [5]. The 
livers, the largest and least affected organ, from a 
homozygous null, heterozygous and wild type littermate 
from a heterozygous ∆176/+ mating pair were isolated 
and lysates probed via western blot with a monoclonal 
antibody raised against serine 20 of human TRP53, 
which cross reacts with mouse TRP53. Western analysis 
showed two bands of proteins ~50kD (Figure 1E) as 
observed previously [5]. Our western blot observation 
and analysis of the ∆176 allele showed no detectable 
protein, suggesting that the protein might be degraded 
since the antibody raised against serine 20 should 
have been able to detect the truncated protein. The 
heterozygotes for this allele produce less WT TRP53 
than that observed in the wild type littermates (β-tubulin 
was used as a loading control (Figure 1E)). In order 
to confirm the observed absence of the protein in the 
∆176 mutant, we performed an ELISA using antibodies 
Figure 1: Generation of SJL/J ∆176.Trp53 mice. A. Design of the guides (sgRNA) targeting exon 4 that resulted in a 176 base 
pair deletion (∆176) (WT: wild type). B. Sequencing chromatograms that show the wild type (WT) littermate, the heterozygote mutant 
(HET∆176) and the homozygous null mutant (HOM ∆176). C. PCR genotyping assay that shows the wild type (+/+), heterozygous (+/-) 
and null (-/-) mice. D. The predicted amino acid sequence resulting in the deletion and generation of a stop codon. Blue and black letters 
show the amino acid sequence from alternating exons; red letters show predicted amino acid overlap splice site and green letters show 
the new amino acid sequence as a result of the deletion and subsequent frameshift and stop codon (*). E. Western blot of TRP53 and 
β-TUBULIN (loading control) showing the absence of the protein in the liver in the -/- mouse, and reduced amount of protein in the +/- 
mice (n = 3 experiments). Arrowheads indicate the position of the TRP53 and tubulin protein. F. Quantification of the amount of TRP53 
protein by ELISA in the +/+ (gray bar), +/- (hatched bar) and -/- (white bar) mice (n = 4, 2 duplicate experiments and at 2 concentrations). 
Significant differences were determined by the student t-test.
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directed towards the N-terminus to confirm the absence 
of the protein in mutant mice and to quantify the amount 
of protein in wild-type and heterozygous mice (Figure 
1F). The ELISA confirmed the western blot results, 
revealing that the amount of TRP53 in the livers (10uL 
of lysate) was 1929 pg/mL in +/+, 422 pg/mL in the +/- 
and 13 pg/mL in the -/-. Considering the standard error 
of detection in the -/- mice was 88 pg/mL, the amount in 
the null can be assumed to be zero.
Survival of Trp53-/- and Trp53+/- mice
Mice carrying the ∆176 allele were further 
characterized for tumor spectrum and survival. The 
absence of TRP53 significantly (P = 0.02) shortens the 
lifespan of the mice from ~one year to a median of 12 
weeks (Figure 2). At 35 weeks, all of the homozygous 
null mice (N = 5) and four of 14 heterozygous mice had 
died, but none of the wild type mice (N = 6) had died. 
Three of the 10 heterozygous mice that lived showed 
signs of tumorigenesis. The reduction in survival has 
been observed before in at least five other strains of mice 
with TRP53 mutations, suggesting that regardless of the 
genetic background, the loss of TRP53 reduces survival 
[14-16, 18]. 
The SJL/J ∆176.Trp53-/- mice have shown a faster 
development of neoplasticity than the tumor prone model 
BALB/c, or tumor resistant models, such as C57BL/6 
(Table I) which suggests that the genetic background 
can modulate the phenotype even of a strong tumor 
suppressor such as TRP53.
Tumor spectrum of the TRP53 null mice
No tumors were detected or observed in the wild 
type littermates of the mice at 35 weeks of age. TRP53 
null (-/-) SJL/J mice developed thymic lymphomas 
(40%), testicular teratomas (40%) or were found dead 
without any visible tumors (20%) (Figure 3A). The 
heterozygous (+/-) mice developed sarcomas (15%) or 
were found dead without tumors, and therefore, non-
cancer related cause of death (7%) (Figure 3A); none 
developed thymic lymphomas or testicular teratomas. 
There was no gender bias in the development of thymic 
lymphomas, and only half of male SJL/J ∆176.Trp53-
/- mice developed testicular teratomas. A shift to thymic 
lymphomas is consistent with the effects of Trp53 
nullizygosity in other strains [14, 16-18],
Upon closer examination of the major types of 
tumors derived from +/- and -/- mice, the following 
was observed (Figure 3B-3E): The thymic lymphomas 
exhibited canonical neoplastic round cells (Figure 3B) 
with a high mitotic rate (red arrowheads) of >20 mitotic 
figures per high powered field (hpf). Necrosis was 
minimal, but there were numerous apoptotic cells (white 
circles) throughout the mass. The mice also showed 
variable splenomegaly due to infiltration by small 
clusters of neoplastic lymphocytes. These features are 
typical of Trp53-/- tumors observed in previous models 
[14, 16].
The testicular tumor masses which were isolated 
from -/- mice were classical teratomas, comprised 
of neoplastic tissues from all three germ layers. 
Accordingly, the tumors were composed of a mixture 
of cell types (Figure 3C): ectoderm (neuropil, red 
asterisks), mesoderm (bone, arrow; cartilage, arrowhead; 
adipose tissue and muscle), and endoderm (squamous to 
columnar ciliated epithelium with goblet cells consistent 
with respiratory epithelium, black asterisks). The 
neoplastic cells in all of the teratomas had a high mitotic 
rate (>20 mitotic figures/hpf), and also showed areas of 
necrosis and/or hemorrhage.
The third type of tumor observed in +/- mice but 
not in -/- SJL/J mice were rhabdomyosarcomas (Figures 
3D). These tumors were composed of neoplastic cells that 
were primarily spindle cells, with a smaller proportion 
of round cells, as well as some multinucleated cells 
(arrows) and strap cells (asterisks). The neoplastic cells 
have a high mitotic rate (>10 mitotic figures/hpf) and 
mild necrosis was seen in the tumor. The spleens were 
large due to plasmacytosis (asterisks), and the red pulp 
have a marked increase in megakaryocytes (arrowheads) 
(Figure 3E). 
In summary, TRP deficiency in a SJL/J background 
shifts the cancer spectrum from primarily Hodgkin’s 
and non-Hodgkin’s lymphoma to thymic lymphomas, 
testicular teratoma and rhabdomyosarcomas. 
Figure 2: Survival of SJL/J ∆176.Trp53 mice. Graph 
showing a survival curve of -/- (black line), +/- (gray line) and 
+/+ littermate (dotted line) mice within the first 35 weeks. See 
text for statistical details.
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Incidence and time-of-onset of thymic lymphomas
As compared to refractive strains such as C57BL6/J 
or 129S, which show >65% incidence rate for thymic 
lymphomas, fewer SJL/J mice developed thymic 
lymphomas (40%), matching more closely to the tumor 
prone strain BALB/c (54%) (Table I). However, thymic 
lymphomas in the refractive strains took longer to develop 
than in the cancer-prone strains. For example, the average 
time-of-onset of thymic lymphomas exceeded 17 weeks in 
C57BL6/J or 129S mice, but was only 12 weeks in SJL/J 
mice (Table 1). Thus, tumor prone strains have a lower 
propensity to develop thymic lymphomas, but develop 
them much faster than the more refractive strains. This 
suggests that the genetic background may play a role 
in modulating the effect of Trp53 nullizygosity. It also 
suggests Trp53 knockout in SJL/J mice offer a more 
operationally convenient timespan for the study of thymic 
Figure 3: Tumor spectrum of SJL/J ∆176.Trp53 mouse. A. Pie charts showing the tumor spectrum distribution of the +/- and -/- 
mice after 35 weeks. B. Hematoxylin and Eosin (H&E) staining of a thymic lymphoma showing cells with high mitotic rate (red arrows) 
and apoptotic cells (circled in white). C. H&E staining of the testicular teratoma showing neoplastic tissues from ectoderm (neuropil, red 
asterisks), mesoderm (bone, arrow; cartilage, arrowhead), and endoderm (black asterisks). D. H&E staining of a rhabdomyosarcoma showing 
neoplastic cells that are primarily spindle cells, with a smaller proportion of round cells, as well as some multinucleated cells (arrows) 
and strap cells (asterisks). E. Splenomegaly was associated with ∆176.Trp53 -/- or +/- mice. Closer examination shows plasmacytosis 
(asterisks), and an increase in megakaryocytes (arrowheads) as seen by H&E staining. 
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lymphomas.
Genomic analysis of strain haplotype sharing 
nominates putative candidate modifiers of 
Trp53-/- mice
The commonly used laboratory mouse strains are 
descended from a small founder pool of individuals and 
thus only capture a limited amount of genetic diversity. 
Across more than 97% of the mouse genome, the genetic 
variation present in classical laboratory strains can be 
reconciled into fewer than 10 distinct haplotypes. Thus, 
we reasoned that putative modifiers of the strain-specific 
Trp53-/- tumor spectrum may reside in genomic regions 
where the refractive C57BL/6J and 129S1/SvImJ strains 
carry the same haplotype, but where the susceptible SJL/J 
and BALB/cJ strains both carry distinct haplotypes. 
Included in the tumor resistant phenotype group are also 
FVB/NJ and C3H/J, which according to JAX repository 
data, develop a similar tumorigenic phenotype as the 
C57BL6/J mice (JAX Stock # 002899 and #002547, 
unpublished data). Using the known haplotype patterns 
that are shared or distinct among strains, we identified 
distinct regions that could be associated with putative 
tumor spectrum modifiers. Overall, only 0.207% of 
the mouse genome (~5.45Mb) exhibited this expected 
haplotype profile across these six strains (Figure 4A). We 
grouped these haplotypes together based on the genes in 
which they harbored into six distinct categories, including 
haplotypes that harbored at least one known (i) cancer 
gene, (ii) DNA repair gene, (iii) immune system gene, (iv) 
non-neoplastic gene, (v) genes with unknown function 
and (vi) gene deserts (Figure 4B). After removing gene 
Figure 4: Patterns of strain haplotype sharing localize candidate regions harboring Trp53-/- modifiers. A. The standard 
house mouse karyotype is displayed. Gray dots denote the positions of genomic intervals where the pattern of haplotype sharing among 
strains mirror trends in their Trp53-/- tumor spectrum. B. Pie chart showing the function/pathology associated with at least one gene found 
in the haplotypes as observed in A. C. Pie chart showing the function/pathology after removing the haplotype that had either no known 
genes or genes with unknown function.
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deserts and unknown function genes, we reanalyzed 
these data (Figure 4C). The pie charts generated show 
that the majority of the genes in these potential modifier 
regions are known to be directly associated with cancer, 
or function in DNA repair or the immune system, which 
are known to influence and modify tumorigenesis 
(Supplementary Figure I). Several compelling candidate 
genes reside in these regions, including genes Egfr, 
Rad51b, and Foxp1, which all have been shown to modify 
p53 tumorigenesis, as discussed below. Therefore, we 
have identified the likely/putative/probable genomic 
regions harboring Trp53 modifiers that make strains such 
as BALB/cJ and SJL/J tumor prone. 
DISCUSSION
While the absence of functional TRP53 (also 
known as p53 in humans, TP53 in mouse) in humans 
causes Li Fraumeni syndrome, the loss of the distal end of 
chromosome 17p13.1 has been linked to a wide spectrum 
of early-onset cancers and acceleration of tumor growth 
[13]. In mice, the loss of TRP53 activity is used to generate 
unique mouse models for studies in transcriptional 
regulation, cell cycle regulation, apoptosis, and genome 
instability [1-3, 5-9, 13-21]. In addition, TRP53 has been 
mutated to rescue embryonic lethality. For example, to 
study non-homologous end joining in mouse models, 
the removal of the Trp53 gene rescues the embryonic 
lethal DNA repair protein Ligase IV [43]. Of relevance 
to this study, TRP53 nullizygosty was successfully used 
to accelerate tumorigenesis in a tumor prone mouse. This 
is a unique model that can be used for rapid cancer and 
therapeutic studies. In addition, by adding this model to 
the library of current TRP53 mutated models, the genetic 
haplotypes that modify such as a strong tumor suppressor 
can be evaluated.
Based on this evidence, we used CRISPR-Cas9 
to delete part of exon 4 (or exon 3 depending on the 
functional ATG site, see Figure 1A) on the TRP53 gene, 
with the goal that this would generate a TRP53 knock-
out, since most of the domains for TRP53 function lie 
downstream or are a part of this exon. Such a genetic 
modification of this gene would lead to an acceleration 
of tumorigenesis and facilitate the testing of novel 
combinations of chemotherapeutics. As predicted, 
Trp53 nullizygosity has accelerated the pace of tumor 
development leading to a decrease in survival. The 
speed with which these tumors appear is remarkably 
fast - 12 weeks on average, as compared to other models 
(Table 1). Therefore, this model is useful to study rapid 
tumorigenesis in mouse models. 
We also showed that a decrease (null) of TRP53 
changed the tumor spectrum from a non-Hogdkin’s like 
disease to thymic lymphoma in SJL/J mice, similar to 
that observed in other strains such as seen in Table I. 
When polymorphisms are used to classify similar mice, 
BALB/cJ, C57BL/6J and 129S/J are quite diverse from 
SJL strains [44, 45]. Yet, thymic lymphomas appear in 
all of these strains. The data presented here in Table I 
exemplify canalization, which is defined as a measure of 
the ability of a population to produce a similar phenotype 
regardless of variability of its environment or genotype. 
The lack of fully functional TRP53 is a powerful driver 
of canalization, that regardless of the genotype leads to a 
single major phenotype (i.e., thymic lymphomas).
However, there is a caveat to this conclusion. In the 
context of Trp53 nullizygosity, the tumor prone strains 
SJL/J and BALB/c show the lowest incidence of thymic 
lymphomas but they develop much faster as compared to 
C57BL6/J and 129S/J, which show the highest frequency 
of thymic lymphomas, but they develop much slower 
(Table I). These results lead us to speculate that the link 
between Trp53 nullizygosity and tumorigenesis may not 
be as simple as the removal of a checkpoint in the cell 
cycle, ablation of apoptosis or any one simple step in a 
pathway, but a more complex interplay between different 
genomes and the propensity to develop cancer.
Based on the notion that the genome can change the 
phenotype of an assumed strong canalized gene such as 
Trp53, we surveyed the literature and JAX repository data, 
and analyzed the genomic differences based on haplotypes 
between tumor prone strains and tumor resistant strains. 
Here we have identified a number of likely/putative/
probable genomic regions harboring Trp53 modifiers that 
make strains such as BALB/cJ and SJL/J tumor prone. 
Genetic and functional tests will be required to evaluate 
whether and how these putative candidates may modulate 
the landscape of tumor formation in the absence of 
Table I: Time of onset of neoplasias in Trp53-/- mice
Strain Mean time of onset neoplasias in weeks incidence rate of thymic lymphomas Reference
C57BL/6 20.0 0.77 Donehower, et al [16]
C57BL/6J 17.2 0.79 Jacks, et al [14]
129S/J 18.0 0.65 Olive, et al; Donehower, et al [18, 17]
BALB/c 15.4 0.54 Kupperwasser, et al [15]
SJL/J 12.0 0.40 This Study
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Trp53-/-. The function of specific genes such as Egfr, 
Rad51b, and Foxp1 have been shown to be modulated 
by Trp53 [46-48]. A specific example is that mutations 
in p53 amplify EGFR family signaling to promote 
mammary tumorigenesis [46]. RAD51B is a homologous 
recombination DNA repair protein that interacts with 
TRP53 [49, 50], and its activity influences cell cycle 
checkpoint control, independent of its role in homologous 
recombination in breast cancer [51]. It is also known that 
RAD51B, being a homologous recombination protein, 
shares its function to maintain genome stability with 
TRP53 [52, 53]. FOXP1 is a transcription factor essential 
for the development of major organs and known to be a 
tumor suppressor in prostrate and breast cancers [54, 55]. 
In fact, Foxp1 directly represses p53-dependent regulatory 
proteins in neoplastic B-cells, suggesting a strong role in 
immune modulation [56]. As we currently understand 
normal anti-cancer responses, a functional immune system 
is a key component that suppresses cancer [57-59]: Foxp1 
controls mature B-cell survival and development, and 
is a regulator for CD4+ T cells [60, 61]. Thus, it is also 
likely that Foxp1 is an essential component that controls 
the lymphoid immune system, and thereby a modulator 
of tumorigenesis. In all of these cases, there are direct 
or indirect mechanisms that could be employed by these 
genes to modulate Trp53-dependent tumorigenesis.
Interestingly, known gene products of Trp53 
modifiers, such as MDM2, MDM4 and CDKN2A 
(p14(ARF)), did not appear in our analysis [2]. It is 
possible that the aforementioned genes are modifiers of 
Trp53 mutations resulting in different tumor spectrums, 
rather than a complete loss or gain of TRP53 that changes 
the tumor incidence, which was the analysis done herein.
Genetically Engineered Mouse Models (GEMMS) 
are key to testing novel chemotherapy and immunotherapy 
compounds [62]. However, tumors may take more than 
several months to develop. To shorten tumor latency time, 
Trp53 is often deleted [63, 64]. Also, the arising tumors 
from a TRP53 null mouse can be directly tested for drug 
efficacy studies (for summary see: [62]). This mouse can 
be used as a model to test T-cell malignancies, testicular 
teratomas and rhabdomyosarcomas, with the advantage 
that it is faster than any other available model.
The concept of whether genetic background 
influenced the tumor incidence or spectrum of Trp53-/- 
mice was tested decades ago: Donehower et al (1995) 
studied Trp53-/- and +/- mice and their wild-type 
littermates from either 129Sv or mixed C57BL/6 × 129/Sv. 
The 129/Sv mice showed accelerated tumorigenesis (Table 
I) compared with p53-deficient counterparts of C57BL/6 × 
129/Sv genetic background, the 129/Sv mice resemble the 
C57BL/6 strainwith respect to tumor onset (Table I). This 
suggests that the genetic background indeedmodulates 
the TRP53 effect on tumor incidence. We have compared 
multiple studies (Table I), and show that different genetic 
backgrounds can remarkably influence tumor onset.
This study did not analyze the tumor spectrum 
of heterozygous mice. In addition, we reported data up 
to 35 weeks when a quarter of the heterozygous mice 
showed tumors or were found dead. Heterozygous mice 
express less than half the amount of TRP53 in their 
tissues as compared to wild type tissues. It is understood 
that Trp53+/- cells have the propensity to develop loss 
of heterozygosity (LOH) depending on the type of cell. 
These two aforementioned phenomena, the lowered 
amount of TRP53 and LOH, potentially drive the tumor 
onset and spectrum in the heterozygous mice [5, 6, 53]. 
Dissecting the two mechanisms (dose of TRP53 and LOH) 
that would contribute to a heterozygous cell’s propensity 
to become neoplastic in this tumor prone mouse model is 
a subject of future study.
Here, we present a mouse model of Trp53 
inactivation in the tumor prone background SJL/J. This 
genetic modification of Trp53 leads to rapid tumorigenesis 
as compared to current models. Further, apart from the 
common thymic lymphomas and rhabdomyosarcomas, 
they also exhibit testicular teratomas. These models can 
now join the pantheon of Trp53 mutations that can be 
used to further dissect the role of TRP53 in the context of 
tumor-prone models versus tumor-resistant models, and 
reveal genetic and epigenetic cancer etiologies. 
MATERIALS AND METHODS
Mice
SJL/J mice used in this study were obtained from, 
and bred and housed at The Jackson Laboratory (Bar 
Harbor, Maine). Mice were provided food and water ad 
libitum and were housed on a 12-hour light, 12-hour dark 
cycle. All procedures were approved by The Jackson 
Laboratory Institutional Animal Care and Use Committee 
(IACUC). 
CRISPR mediated knock out of Trp53
Approximately 2-5 picoliters of Cas9 mRNA 
(at 100 ng/ul, Trilink), Cas9 protein (at 30 ng/ul, 
PNABio), and two sgRNAs (at 50 ng/ul each) were 
delivered by microinjection into the pronucleus of 
SJL/J zygotes as previously described [40]. Truncated 
guides (TRU-sgRNAs) [41] were designed with the 
assistance of online software, Breaking Cas [42], 
in order to minimize off-target cutting. The guides 
were designed to target exon 4 of the Trp53 gene 
(target sites: 5’-GAGCTCCTGACACTCGGA and 5’- 
GCCAAGTCTGTTATGTGCA) and were made using 
a HiScribe kit (New England Biolabs). Microinjected 
zygotes were transferred to pseudopregnant females, 
brought to term and screened at two to three weeks of 
Genes & Cancer91www.Genes&Cancer.com
age by PCR flanking exon 4. These founder mice were 
backcrossed with SJL/J, and resulting mice heterozygous 
for the mutation were then inbred to homozygosity.
Survival criteria
Mice were monitored daily from the time of birth 
and diagnosed with a tumor as soon as a visible abnormal 
growth appeared. The tumors were allowed to grow until 
the mice showed signs of illness and required euthanasia 
which then was recorded as the date of death. The need for 
euthanasia was independently verified by our Clinical and 
Laboratory Animal Medicine personnel. In addition, mice 
that were found dead were necropsied and diagnosed for 
the cause of death. All mice were terminated at 35 weeks 
of age.
Western blotting
Snap frozen tissues were pulverized with a 
Spectrum Bessman Tissue Homogenizer (Fisher Scientific 
# 08-418-3) on dry ice. A portion of each tissue was 
transferred into a pre-weighed 1.5mL tube and the weight 
of each tissue sample was determined. The tissue samples 
were subsequently suspended in 100uL of chilled RIPA 
(Millipore-Sigma # R0278) with complete mini protease 
inhibitors (Roche #11836153001) and PhosSTOP 
phosphatase inhibitor (Roche #4906845001) per 40ug of 
tissue and homogenized on ice for 10 s with individual 
sterile pestles (Fisher Scientific #12-141-364). After 5 min 
on ice, homogenization was repeated. After incubating on 
ice for a further 30 min with a brief vortex every 5 min, the 
samples were spun at 10,000 × g for 10 min at 4°C. The 
supernatants were decanted and their protein concentration 
determined by the Bradford Assay (Bio-Rad # 500-0205) 
using BSA (Bio-Rad # 5000206) for the standard curve. 
Gel samples were prepared and denatured at 95°C for 5 
min. 50 ug total protein per tissue was separated on 10% 
Bis-Tris Protein Gels (Fisher Scientific #NP0302BOX) 
with MOPS SDS Running Buffer (Fisher Scientific 
#NP0001) in duplicate. The gels were transferred to 
nitrocellulose (Fisher Scientific #IB3010-32) using an 
iBlot Gel Transfer Device (Fisher Scientific). The blots 
were blocked in 3% BSA in 25mM Tris·Cl, 2.7mM KCl, 
137mM NaCl and 0.03% TWEEN-20 (TBST) at room 
temperature for 1 h. One blot was then placed in p53 
(1C12) monoclonal antibody (Cell Signaling Technology 
#2524) diluted 1:2000 in 3% BSA-TBST and the second 
blot was placed in 3% BSA-TBST with a β-tubulin 
antibody (Millipore-Sigma #T4026) diluted 1:10,000. 
Both blots were agitated on a shaker at 4oC overnight. 
The blots were washed with TBST for 15min and then 
with 5 min washes then placed in 3% BSA-TBST with 
goat anti-Mouse IgG (H + L)-HRP conjugate (Bio-Rad # 
170-6516) diluted 1:20,000 for 1 h at room temperature. 
After washing with TBST for 15min and then with 5 min 
washes, the blots were developed with SuperSignal West 
Pico PLUS Chemiluminescent Substrate (Fisher Scientific 
# PI-34087) and imaged with a G-box (Syngene).
ELISA for TRP53 quantification
Samples used for western blotting (see above) 
were quantified using the Abcam Mouse p53 ELISA Kit 
(Abcam # ab224878).
Statistics and protein prediction:
 For survival curves, P-values were calculated by 
log-rank (Mantel-Cox) test using Prism7 v7.0d software. 
Protein sizes were predicted from the Protein Calculator 
(v3.4) (http://protcalc.sourceforge.net/) 
Genome queries
Genome-wide haplotype strain distribution patterns 
were downloaded from the Mouse Phylogeny Viewer 
(http://msub.csbio.unc.edu/). A custom Perl script was 
used to identify genomic regions harboring a single shared 
haplotype between C57BL/6J, FVB/NJ, C3H/HeJ and 
129S1/SvImJ, a second distinct haplotype in SJL/J, and a 
third haplotype in BALB/cJ. These genomic regions were 
then intersected with genes in the mm10 RefSeq database. 
We performed a manual inspection of the resulting gene 
list to nominate putative modifiers of Trp53 that could 
underlie observed strain differences in the tumor spectrum. 
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